About Curative Technologies
Developer of therapeutics utilizing naturally occurring human growth factors. The initial indication for this technology is in treating chronic non-healing wounds. The product, called Procuren, is produced from a patient's own blood. Procuren, an autologous platelet derived wound healing formula, is a naturally occurring complex mixture of growth factors that promotes the growth of skin, soft tissue, and blood vessels. In November 1990, the company completed phase 2 clinical trials of a second would healing product and is currently seeking authorization for the FDA to begin phase 3 trials. Chronic non-healing wounds are common in patients with diabetes and venous stasis disease, as well as in patients who are immobilized and afflicted with pressure sores.